Kwok-kin Wong

发表

Acquired Resistance to Dasatinib in Lung Cancer Cell Lines Conferred by DDR2 Gatekeeper Mutation and NF1 Loss

P. Hammerman, A. Bass, N. Gray, 2013, Molecular Cancer Therapeutics.

Targeting wild-type KRAS amplified gastroesophageal cancer through combined MEK and SHP2

James M. McFarland, S. Carr, R. Beroukhim, 2018, Nature Medicine.

H3K9 methyltransferases and demethylases control lung tumor-propagating cells and lung cancer progression

B. Aronow, Fei Li, T. Schlaeger, 2018, Nature Communications.

Regression of Drug-resistant Lung Cancer by the Combination of Rosiglitazone and Carboplatin Cancer Therapy: Preclinical

Jessica M. Silvaggi, G. Demetri, R. Padera, 2022 .

Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2

A. Redig, H. Ji, P. Hammerman, 2017, Nature Communications.

EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumors to TopoII inhibitors

P. Hammerman, Kwok-Kin Wong, Christine M. Fillmore, 2014, Nature.

Overcoming EGFR T790M and C797S resistance with mutant-selective allosteric inhibitors

P. Jänne, Jennifer L. Harris, M. Eck, 2016, Nature.

LKB1 loss links serine metabolism to DNA methylation and tumorigenesis

D. Hayes, P. Hammerman, Kwok-Kin Wong, 2016, Nature.

HIF2α cooperates with RAS to promote lung tumorigenesis in mice (Journal of Clinical Investigation (2009) 119, (2160-2170) doi:101172/JCI38443)

D. Hayes, Kwok-Kin Wong, W. Kaelin, 2009 .

Pan-ERBB kinase inhibition augments CDK4/6 inhibitor efficacy in oesophageal squamous cell carcinoma

Henry W. Long, M. Meyerson, A. Bass, 2021, Gut.

Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma

A. Bass, Kwok-Kin Wong, A. Rustgi, 2019, Nature Communications.